The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Marker Therapeutics Inc shares valued at $35,472 were purchased by ELMS STEVE on Dec 23 ’24. At $3.20 per share, ELMS STEVE acquired 11,085 shares. The insider’s holdings grew to 325,370 shares worth approximately $0.48 million following the completion of this transaction.
Also, New Enterprise Associates 16, purchased 554,250 shares, netting a total of over 1,773,600 in proceeds. Following the buying of shares at $3.20 each, the insider now holds 1,625,678 shares.
As published in their initiating research note from Canaccord Genuity on March 05, 2025, Marker Therapeutics Inc [MRKR] has been a Buy and the price target has been revised to $8. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in late March. As of March 19, 2021, Cantor Fitzgerald has initiated its “an Overweight” rating for MRKR. Earlier on May 12, 2020, Piper Sandler downgraded its rating. Their new recommendation was “a Neutral” for MRKR stock which previously was a “an Overweight”.
Analyzing MRKR Stock Performance
On last trading session,, Marker Therapeutics Inc [NASDAQ: MRKR] plunged -2.00% to $1.47. During the last five days, there has been a drop of approximately -21.39%. Over the course of the year, Marker Therapeutics Inc shares have dropped approximately -52.73%. Shares of the company reached a 52-week high of $3.3800 on 01/03/25 and a 52-week low of $0.9500 on 04/07/25.
Support And Resistance Levels for Marker Therapeutics Inc (MRKR)
According to the 24-hour chart, there is a support level at 1.4312, which, if violated, would cause prices to drop to 1.3925. In the upper region, resistance lies at 1.5075. The next price resistance is at 1.5451. RSI (Relative Strength Index) is 51.29 on the 14-day chart, showing neutral technical sentiment.
